Physician profile
Katisha Patterson
NPI 1982154464
$1,107.46
in general payments reported to CMS, 2019-2025
19 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $249 · 2023: $303 · 2024: $100 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.15 |
| Education | $144.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $339.72 | 2021-2024 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $102.81 | 2022-2025 | Ova1 |
| Mayne Pharma Commercial LLC | $101.87 | 2021-2023 | |
| Agile Therapeutics, INC. | $72.38 | 2021-2022 | |
| Millicent US INC | $69.74 | 2025 | Femring, Intrarosa |
| Abbvie INC. | $68.61 | 2021-2025 | |
| Mylan Pharmaceuticals INC. | $57.76 | 2021-2022 | |
| Therapeuticsmd, INC. | $42.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.90 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $38.17 | 2024 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $29.53 | 2023 | Gardasil 9 |
| Novo Nordisk INC | $23.30 | 2025 | Ozempic |
| Biohaven Pharmaceuticals, INC. | $21.53 | 2021 | |
| Scynexis, INC. | $19.81 | 2022 | |
| Shield Therapeutics INC | $18.19 | 2023 | Accrufer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $17.34 | 2022 | |
| Daiichi Sankyo INC. | $17.07 | 2025 | Injectafer |
| Pfizer INC. | $14.49 | 2021 | |
| Hologic Sales and Service, LLC | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katisha Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.